Abstract
Increasingly real-world evidence (RWE) is also appraised to support the value of new health technologies that ensures timely patient access. RWE is considered as evidence gathered outside of RCTs and derived from data obtained from non-randomized trials, observational studies, or databases amongst others. This analysis aims to assess the value of RWE in recent HTA appraisals for melanoma drugs in England, France, Canada, Australia, Germany, Scotland, and the Netherlands.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
